Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Fujifilm’s US Bioscience Site Now Up and Running
December 6, 2019
- Daiichi Sankyo Reps Continue Heavy Pitches for Tarlige in September: Impact Track
December 6, 2019
- Keytruda Remains No. 1 in November Japan Drug Ranking: Encise
December 6, 2019
- Boston Biomedical Ties Up with 3 Institutions in Oncology Research
December 5, 2019
- With Audentes Buyout, Astellas Poised to Position “Genetic Regulation” as 5th Biz Pillar
December 4, 2019
- Original Maker Recalls Nizatidine over Carcinogen Risks
December 4, 2019
- Vyvanse Now Available in Japan 6 Months after Listing
December 4, 2019
- Astellas, Seattle Genetics Join Hands with US Merck for ADC/Keytruda Combo
December 4, 2019
- Takeda Launches Zafatek 25 mg for Patients with Renal Dysfunction
December 4, 2019
- Shire Rolls Out Kit Version of Advate IV in Japan
December 4, 2019
- Idelvion’s 3500 IU Vials Available in Japan: CSL Behring
December 4, 2019
- Lenvima’s Add’l Thyroid Cancer Use Accepted for Chinese Regulatory Review
December 3, 2019
- Zykadia’s Film-Coated Tablets Now Available
December 3, 2019
- Full Showdown Starts as Mylan’s Nesp Biosimilar Reaches Market
December 3, 2019
- Crysvita’s Japan Launch Set for Dec. 6: Kyowa Kirin
December 3, 2019
- Chugai Completes Transfer of 3 Dermatology Products to Maruho
December 3, 2019
- Astellas to Buy Gene Therapy Player Audentes for US$3 Billion
December 3, 2019
- Shionogi Introduces AI Chatbot for Xofluza Inquiries from Medical Professionals
December 3, 2019
- Satralizumab Reduces Risk of NMOSD Relapses: Chugai
December 2, 2019
- JT’s Enarodustat 4th HIF-PH Inhibitor Filed in Japan
December 2, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…